Tevosol Overview

  • Founded
  • 2015

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees
  • Latest Deal Type
  • M&A

  • Investors
  • 1

Tevosol General Information

Description

Developer of a portable warm perfusion devices designed to preserve human organs in an artificially created human body like environment. The company's device uses advanced transplant technologies to offer better recovery of organs, resuscitation of dysfunctional organs and offers longer preservation of function with the opportunity for ex-vivo treatment, enabling medical professionals to transplant human body organs with full safety.

Contact Information

Website
www.tevosol.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Other Devices and Supplies
Parent Company
Primary Office
  • 4261 - 10230 Jasper Avenue
  • Edmonton, Alberta T5J 4P6
  • Canada
+1 (587) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tevosol Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 09-Feb-2021 00.000 Completed Generating Revenue
4. Seed Round 15-Aug-2019 00.000 00.000 Completed Startup
3. Accelerator/Incubator 05-Aug-2019 000 Completed Startup
2. Angel (individual) 29-Jun-2016 $2M $2M Completed Startup
1. Accelerator/Incubator 01-Jan-2016 $25K Completed Startup
To view Tevosol’s complete valuation and funding history, request access »

Tevosol Patents

Tevosol Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018368000-A1 Apparatus for perfusion of an excised organ Pending 20-Nov-2017 0000000000
CA-3080411-A1 Apparatus for perfusion of an excised organ Pending 20-Nov-2017 0000000000
EP-3713410-A1 Apparatus for perfusion of an excised organ Pending 20-Nov-2017 0000000000
EP-3713410-A4 Apparatus for perfusion of an excised organ Pending 20-Nov-2017 0000000000 0
US-20200367488-A1 Apparatus for perfusion of an excised organ Pending 20-Nov-2017 A01N1/0247
To view Tevosol’s complete patent history, request access »

Tevosol Executive Team (7)

Name Title Board Seat Contact Info
Walter Maciurzynski Chief Financial Officer
Darren Freed Ph.D Founder & Chief Scientific Officer
Jayan Nagendran Ph.D Co-Founder & Chief Medical Officer
Carolyn Nalder Senior Project Manager
David Moon Vice President, Strategy & Business Development
You’re viewing 5 of 7 executive team members. Get the full list »

Tevosol Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tevosol Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
TEC Edmonton Accelerator/Incubator 000 0000 000000 0
TMC Innovation Accelerator/Incubator Minority 000 0000 000000 0
To view Tevosol’s complete investors history, request access »